Literature DB >> 30203750

Clinical therapeutic effect and safety of celecoxib in treating knee osteoarthritis.

Zhiping Yu1, Lijun Zhao2, Changzheng Yu1, Jianfei Bi1, Xiaofeng Yu1.   

Abstract

The clinical therapeutic effect and safety of celecoxib in treating knee osteoarthritis were observed. 180 patients who have been confirmed with knee osteoarthritis in our hospital were selected as research objects. They were randomly divided into research group and control group, each containing 90 patients. The control group was given with diclofenac sodium therapy, while the research group was subjected to celecoxib therapy. The total therapeutic response rates between the two groups were observed and compared. The total therapeutic response rate of research groups was relatively higher, P<0.05. There was no significant difference in pain score, erythrocyte sedimentation rate (ESR), quality of life score (QLS) between two groups before treatment, P>0.05. However, these indexes of research group were superior then the control group after treatment,P<0.05. In addition, the rate of adverse reaction of research group was also lower than that of control group, P<0.05. Using celecoxib to treat knee osteoarthritis can significantly improve the total therapeutic rate and reduce the rate of adverse effect.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30203750

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  Effects of low-intensity pulsed ultrasound on knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Haoqian Chen; Zheng Wang; Xinan Zhang; Mingli Sun
Journal:  Clin Rehabil       Date:  2022-05-09       Impact factor: 2.884

2.  Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis.

Authors:  Hetao Huang; Minghui Luo; Haodong Liang; Jianke Pan; Weiyi Yang; Lingfeng Zeng; Guihong Liang; Senrong Hou; Jinlong Zhao; Jun Liu
Journal:  Pain Med       Date:  2021-02-23       Impact factor: 3.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.